Antipsychotic Safety in Chronic Kidney Disease

General Principles for Antipsychotic Use in CKD

All antipsychotics require consideration of GFR when prescribing, with regular monitoring of eGFR, electrolytes, and therapeutic drug levels when indicated, as recommended by the American Journal of Kidney Diseases 1, 2
Patients with CKD are more susceptible to medication adverse effects due to impaired metabolism and increased risk of drug interactions from polypharmacy, according to the American Journal of Kidney Diseases 1

For patients with mild to moderate CKD (GFR ≥30 mL/min/1.73 m²), most antipsychotics can be used with standard dosing but require increased monitoring for central nervous system effects, including sedation, confusion, and extrapyramidal symptoms, as recommended by the American Journal of Kidney Diseases 1
For patients with severe CKD and ESRD (GFR <30 mL/min/1.73 m²), start with lower doses (typically 25-50% reduction) and titrate slowly while monitoring for adverse effects, according to the American Journal of Kidney Diseases 1, 2

Monitor eGFR, electrolytes, and assess for central nervous system symptoms (sedation, confusion, extrapyramidal effects) regularly, especially during dose titration, as recommended by the American Journal of Kidney Diseases 1, 2
Temporarily discontinue antipsychotics during serious intercurrent illness that increases risk of acute kidney injury, according to the American Journal of Kidney Diseases 2
Review all over-the-counter medicines and herbal remedies, as these should be avoided in CKD patients due to unpredictable interactions and nephrotoxicity, as recommended by the American Journal of Kidney Diseases 1, 2

For CKD Stage 4-5 (GFR <30), reduce initial dose by 25-50%, extend dosing intervals, and titrate slowly based on clinical response and tolerability, as recommended by the American Journal of Kidney Diseases 1, 2
Involve a clinical pharmacist in medication management to optimize dosing and reduce adverse events, according to the American Journal of Kidney Diseases 1